Global Acute Kidney Injury Treatment Market, by Type (Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, and Postrenal Acute Kidney Injury), by Treatment (Therapy, and Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,857.8 Mn in 2021 and is expected to exhibit a CAGR of 7.2% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Key players in the market are focusing on growth strategies such seed financing to develop the treatment for acute kidney injury, which is expected to propel growth of the market over forecast period. For instance, in May 2021, Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat acute kidney injury (AKI) announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work. This collaboration help to advance Nephraegis Therapeutics, Inc. lead product through key preclinical activities and prepare company for investigational new drug (IND) submission and clinical development.
Global Acute Kidney Injury Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has drastically affected several clinical trials. Various trials have been paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments. For instance, according to a survey conducted by Medidata Solutions, Inc. (a U.S. based technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.
Browse 27 Market Data Tables and 31 Figures spread through 156 Pages and in-depth TOC on “Global Acute Kidney Injury Treatment Market”- Forecast to 2028, Global Acute Kidney Injury Treatment Market, by Type (Prerenal Acute Kidney Injury, Intrinsic Renal Acute Kidney Injury, and Postrenal Acute Kidney Injury), by Treatment (Therapy, and Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/acute-kidney-injury-treatment-market-4691
Moreover, rise in geriatric population is also expected to aid in growth of the global acute kidney injury treatment market over the forecast period. For instance, according to World Health Organization the number of people aged 85 years and older is projected to rise from 14 million to 19 million by 2020 and to 40 million by 2050 in Europe.
Key Takeaways of the Global Acute Kidney Injury Treatment Market:
- The global acute kidney injury treatment market is expected to exhibit a CAGR of 7.2% during the forecast period due to key companies in the market focusing on growth strategies such as partnership is expected to boost growth of the market. For instance, in September 13, 2021, Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to evaluate Sentien’s ex vivo cell therapy, SBI-101, in patients suffering from acute kidney injury (AKI) associated with sepsis. This patient population includes COVID-19 patients with sepsis-AKI.
- Among distribution channel, hospital pharmacies segment is estimated to hold largest market share in global acute kidney injury treatment market over the forecast period. Increase in the prevalence of acute kidney injury is expected to drive the growth of the segment over forecast period. For instance, according to data published in Medscape in 2020, stated that in the U.S., approximately 1% of patients admitted to hospitals have AKI at the time of admission. The estimated incidence rate of AKI during hospitalization is 2-5%. AKI develops within 30 days postoperatively in approximately 1% of general surgery cases and arises in more than 50% of intensive care unit (ICU) patients.
- Among regions, North America is estimated to hold dominant position in global acute kidney injury treatment market in Key companies operating in the market focusing on growth strategies such as launches in the U.S. is estimated to drive the growth of the segment in 2021. For instance, in October 2018, the association of Mayo clinic and Baxter International Inc. announced the strategic plan to launch Renal Care Center of Excellence (RCCE) in the U.S. with the aim to offer guidance about home hemodialysis, chronic kidney disease management, and in-center hemodialysis to chronic kidney disease (CKD) patients.
- Major players operating in the global acute kidney injury market include Quark Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG., B. Braun Melsungen AG, Fresenius Medical Care, Medtronic, Astellas Pharma Inc., Sentien Biotechnologies, Inc., Teva Pharmaceutical Industries Ltd., Asahi Kasei Medical Co., AM-Pharma B.V, Teleflex Incorporated, Cure Medical, LLC, and Angion Biomedia Corp.
